Mersana Therapeutics Inc. (NASDAQ:MRSN) saw a downside of -3.23% to close Monday at $1.20 after subtracting -$0.04 on the day. The 5-day average trading volume is 4,703,720 shares of the company’s common stock. It has gained $1.2700 in the past week and touched a new high 2 times within the past 5 days. An average of 15,930,170 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 8,937,353.
MRSN’s 1-month performance is -67.12% or -$2.4500 on its low of $0.8014 reached on 07/27/23. The company’s shares have touched a 52-week low of $0.80 and high of $9.62, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, MRSN has lost -79.52% or -$4.6600 and has reached a new high 20 times. However, the current price is down -87.53% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
MRSN stock investors last saw insider trading activity on Apr 27.Carvajal Alejandra (SVP, Chief Legal Officer) most recently sold 3,944 shares at $3.89 per share on Apr 27. This transaction cost the insider $15,342. President & CEO, Protopapas Anna, sold 17,346 shares at a price of $5.74 on Jan 17. Then, on Jan 17, SVP, Chief Sci.&Tech. Off. Lowinger Timothy B sold 6,233 shares at a price of $5.74 per share. This transaction amounted to $35,777.
Valuation Metrics
MRSN stock has a beta of 1.42. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.75 while the price-to-book (PB) in the most recent quarter is 2.00.
Mersana Therapeutics Inc.’s quick ratio for the period ended March 30 was 3.40, with the current ratio over the same period at 3.40. The trailing 12-month EBITDA margin is -763.10%. The firm’s gross profit as reported stood at $230.35 million against revenue of $26.58 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 15.85% to -$56.16 million, while revenue of -$44.92 million was 20.01% off the previous quarter. Analysts expected MRSN to announce -$0.44 per share in earnings in its latest quarter, but it posted -$0.52, representing a -18.20% surprise. EBITDA for the quarter stood at more than -$58.89 million. MRSN stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 231.9 million, with total debt at $35.82 million. Shareholders hold equity totaling $114.39 million.
Let’s look briefly at Mersana Therapeutics Inc. (MRSN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 22.68% to suggest the stock is trending oversold, with historical volatility in this time period at 657.61%.
The stock’s 5-day moving average is $1.1530, reflecting a -2.04% or -$0.0250 change from its current price. MRSN is currently trading -68.59% above its 20-day SMA, -74.25% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -83.81% and SMA200 by-83.54%.
Stochastic %K and %D was 12.05% and 10.80% and the average true range (ATR) pointed at 0.3365. The RSI (14) points at 25.03%, while the 14-day stochastic is at 12.74% with the period’s ATR at 0.3735. The stock’s 9-day MACD Oscillator is pointing at -0.2917 and -1.1095 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Mersana Therapeutics Inc. (NASDAQ: MRSN), Robert W. Baird downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for MRSN stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate MRSN as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
